KRAS and neoplasm: More recently, other studies have also reported emergence of KRAS mutations in liver metastases after anti-EGFR treatment, highlighting the role of intra-tumour heterogeneity as a major contributing factor for intrinsic and/or acquired resistance to anti-EGFR mAbs [19].